| Autor: |
Giovanni Adami, Maurizio Rossini, Thomas Funck-Brentano, Roland Chapurlat, Elena Tsourdi |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
RMD Open, Vol 9, Iss 1 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2056-5933 |
| DOI: |
10.1136/rmdopen-2022-002973 |
| Popis: |
Osteoporosis is a common non-communicable disease with enormous societal costs. Antiosteoporosis medications have been proven efficacious in reducing the refracture rate and mortality; moreover, we have now convincing evidence about the cost-effectiveness of antiosteoporotic medications. However, albeit preventable and treatable, osteoporosis has been somehow neglected by health authorities. Drugs approval has been unnecessarily lengthy, especially when compared with other non-communicable diseases. Herein, we discuss the issue of procrastinating drug approval in osteoporosis and future implications. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
